

1 **Title: A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and**
2 **striking increase in Aortic TGFB1/2 expression**

3

4 Raya Al Maskari¹, Yasmin¹, Sarah Cleary¹, Nikki Figg¹, Sarju Mehta², Doris Rassi³,
5 Ian Wilkinson¹ and Kevin M O'Shaughnessy¹

6

7 ¹ Department of Medicine (EMIT and CVD divisions), University of Cambridge, UK; ²
8 Medical Genetics, Addenbrookes Hospital, UK; ³ Pathology, Papworth Hospital, UK

9

10 **Running title:** LDS4 p.(Arg320Cys) mutation increases TGFβ signaling

11

12 **Corresponding author:** Kevin O'Shaughnessy (kmo22@medschl.cam.ac.uk)

13 Department of Medicine (EMIT Div)

14 Box 110, Level 6 ACCI

15 Addenbrookes Hospital

16 Cambridge CB2 2QQ, UK

17 E – kmo22@medschl.cam.ac.uk

18 P – 44 1223 762578

19

20 **Conflict of interest:** None

21 **Abstract**

22

23 Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder
24 with a range of cardiovascular, skeletal, craniofacial and cutaneous manifestations.

25 LDS type 4 is caused by mutations in TGF β ligand 2 (TGFB2) and based on the
26 family pedigrees described to date, appears to have a milder clinical phenotype,
27 often presenting with isolated aortic disease. We sought to investigate its molecular
28 basis in a new pedigree. We identified a missense variant **p.(Arg320Cys)**
29 (NM_003238.3) in a highly evolutionary conserved region of TGFB2 in a new LDS
30 type 4 pedigree with multiple cases of aortic aneurysms and dissections. There was
31 striking up-regulation of TGFB1 and TGFB2 expression on immunofluorescent
32 staining and western blotting of the aortic tissue from the index case confirming the
33 functional importance of the variant. This case highlights the striking paradox of
34 predicted loss-of-function mutations in TGFB2 causing enhanced TGF β signaling in
35 this emerging familial aortopathy.

36

37 **Keywords:** Loeys-Dietz Syndrome LDS4, TGFB2 mutation, Aortic

38 Aneurysm/Dissection

39

40

41

42

43

44 **Introduction**

45

46 Loeys-Dietz syndrome (LDS) is an inherited autosomal dominant (AD) systemic
47 disorder with a broad phenotypic spectrum of cardiovascular, skeletal, craniofacial
48 and cutaneous manifestations (OMIM #609192). The hallmark of early and
49 progressive aortic root dilatation, predisposes to premature death from dissection
50 and rupture of the aorta [1]. Other classic features include widespread arterial
51 tortuosity, bicuspid aortic valve, bifid uvula/cleft palate and hypertelorism [1]. LDS is
52 caused by disruption to the transforming growth factor beta (TGF β) signaling
53 pathway. TGF β proteins regulate key processes including cell proliferation,
54 angiogenesis and matrix turnover by signaling through serine/threonine kinase
55 receptors (TGFBR1, TGFBR2) and downstream effectors, the SMAD proteins [2].
56 TGF β is synthesized as a dimer bound to a latency associated peptide (LAP) that
57 prevents the cytokine from binding to its receptors [3]. Complex mechanisms also
58 control TGF β sequestration and release by the extracellular matrix (ECM) [3].

59 Mutations in TGFBR1, TGFBR2, TGF β ligands 2 and 3 (TGFB2, TGFB3) and
60 SMAD3 are associated with LDS disease pathogenesis [4-7]. Precise genotype-
61 phenotype correlations are still lacking, but it is proposed that a mutation in any of
62 these genes plus arterial aneurysm/dissection or a family history of LDS is sufficient
63 for the diagnosis [8]. LDS type 4 is caused by mutations in TGFB2 and represents a
64 milder end of the LDS spectrum often with isolated aortic disease presenting in the
65 mid-thirties [9]. To date, less than 20 mutations in TGFB2 have been identified
66 usually in the LAP domain of the protein [6, 9-13]. However, the underlying
67 pathogenic mechanisms remain unclear. Most of the mutations are predicted to be

68 loss-of-function, but their downstream effect appears to be a paradoxical activation
69 of TGF β signaling [14].

70 Here we report a new pedigree with LDS4 and confirm that the causative
71 variant p.(Arg320Cys) (NM_003238.3) causes striking upregulation of TGFB1/2
72 expression in the aorta. This confirms that the variant is functional and corroborates
73 previous reports of an enhanced aortic TGF β “tissue signature” in LDS and other
74 TGF β vasculopathies.

75

76 **Materials and Methods**

77

78 **Data Submission**

79 Phenotype and variant data were submitted into LOVD v.3.0 Build 16
80 <http://medgen.ua.ac.be/LOVDv.3.0/individuals/00000322>.

81

82 **Control Subjects**

83 Formalin-fixed and paraffin embedded (FFPE) aortic tissue from age and gender
84 matched donors (n=5) were obtained from the Transplant service at Addenbrooke’s
85 Hospital (Cambridge, UK). All samples were handled in accordance with the policies
86 and procedures of the Human Tissue Act and had Local and Regional Ethics
87 approval.

88

89 **Immunofluorescence staining**

90 FFPE sections of the surgical specimen were deparaffinised in HistoClear (National
91 Diagnostics, Atlanta, GA, USA) then dehydrated through graduated methanols.
92 Antigen retrieval was performed in pH6 citrate buffer (Vector Laboratories Ltd,
93 Peterborough, UK) using 2100 Retriever (Aptum Biologics Ltd, Southampton, UK).
94 Sections were permeabilised with 0.05% v/v Triton X-100–PBS for 5 min and

95 blocked for 2 h at room temperature with 5% v/v goat serum in 0.05% v/v Triton™ X-
96 100–PBS. Sections were probed with mouse monoclonal to TGFB2 (Abcam,
97 Cambridge, UK) and mouse monoclonal to TGFB1 (Abcam) for 16 h at 4°C at 1:200
98 dilution in 2% v/v goat serum in 0.05% v/v Triton™ X-100–PBS. Slides were then
99 washed for 5 min in 0.05% v/v Triton™ X-100–PBS and incubated in secondary
100 antibody for 1 h at room temperature. Pre-absorbed goat IgG-conjugated Alexa
101 Fluor® 633 secondary antibody (ThermoFisher Scientific, Waltham, MA, USA) was
102 used at 1:200 dilution in 2% v/v goat serum in 0.05% v/v Triton™ X-100–PBS.
103 Sections were counterstained with Sytox® Orange (ThermoFisher Scientific) at
104 1/10,000 in Milli-Q® water for 20 min at room temperature then mounted with
105 ProLong® Gold Antifade Mountant (ThermoFisher Scientific).

106 Images were acquired with a Leica SP8 (Leica Microsystems, Wetzlar,
107 Germany) inverted laser scanning confocal microscope using a 20X 1.4 N.A. dry
108 objective. Acquisition parameters were: 12-bit, 1024 x 1024 pixels, 1.25x and 3x
109 digital zooms, 8000 Hz scan speed, 16-line Kalman filtering and 2 frame
110 accumulation. All images were acquired using identical scan settings.

111

112 **Protein Extraction and Western blotting**

113 Western blotting for TGFB1 and TGFB2 was performed in the case and two of the
114 controls. Three 15µm FFPE sections of each tissue sample were deparaffinised in
115 HistoClear® 3 times. The procedure was serially repeated with 100%, 95% and 70%
116 ethanol, washing twice for 10 min each. Pellets were air dried, re-suspended in
117 Extraction Buffer EXB Plus (Qiagen, Hilden, Germany) containing β-
118 mercaptoethanol and incubated at 4°C for 5 min then at 100°C for 20 min followed
119 by a 2 h incubation at 80°C with agitation and a final incubation at 4°C for 1 min.

120 Samples were then centrifuged at 4°C for 15 min and the protein quantified using
121 Pierce™ BCA protein assay (ThermoFisher Scientific) and stored at -70°C until
122 further use.

123 Ten µg of protein lysates were used for the western blot. Samples were
124 incubated at 70°C for 10 min in Lithium dodecylsulfate (LDS) sample loading buffer
125 (ThermoFisher Scientific) and Bolt® sample reducing agent (ThermoFisher
126 Scientific). Samples for TGFB1 blotting were performed under non-reducing
127 conditions. Protein was separated by SDS-gel electrophoresis in 4-12% gradient Bis-
128 Tris Plus Bolt® gels (ThermoFisher Scientific) at 200V for 30 min and transferred to
129 0.22µM nitrocellulose membrane (ThermoFisher Scientific) using the iBlot2 dry
130 blotting system (ThermoFisher Scientific) at 20V for 10 min. Prior to transfer, gels
131 were equilibrated for 5min in NuPage transfer buffer (ThermoFisher Scientific)
132 containing 10% methanol. Membranes were blocked with 5% w/v milk in TBS buffer
133 for 1 h at room temperature then incubated with primary antibodies in 5% milk w/v in
134 0.1% v/v Tween® 20-TBS for 16 h at 4°C. Anti-TGFB2 (Abcam) rabbit polyclonal IgG
135 antibody was used at 1:500 dilution and β-actin mouse monoclonal IgG
136 (ThermoFisher Scientific) was used as a loading control at 1:1000 dilution. Anti-
137 TGFB1 (Abcam) mouse monoclonal IgG antibody was used at 1:500 dilution and β-
138 actin rabbit polyclonal IgG (Sigma Aldrich, St Louis, MO, USA) was used as a
139 loading control at 1:1000 dilution. Secondary antibodies were incubated in 0.1% v/v
140 Tween® 20-TBS for 1 h at room temperature. Donkey anti-rabbit (LI-COR
141 Biotechnology UK Ltd, Cambridge, UK) IRDye® 800CW and goat anti-mouse
142 (ThermoFisher Scientific) Alexa Fluor® 680 conjugated secondary antibodies were
143 used at 1:5000 dilution. Membranes were washed in 0.1% v/v Tween® 20-TBS 3
144 times for 15 min each between primary and secondary antibody incubations and

145 before visualization. Protein bands were detected using the LI-COR Odyssey
146 system. Signal intensities were normalised against β -actin and quantified using
147 ImageStudioLite software.

148

149 **Results**

150

151 **Pedigree discovery**

152 A 27-year-old man presented with severe pain radiating down his back after lifting a
153 lawn mower into a van. The family history revealed several family members with
154 aortic aneurysms and dissections: his mother (III:6) died following an aortic
155 dissection, a maternal uncle (III:1) had emergency repair of an aortic aneurysm and
156 his maternal grandfather (II:3) had a dissection of an abdominal aortic aneurysm and
157 separate iliac artery aneurysms (Figure 1A). On examination, the only sign was an
158 elevated BP of 240/100 mmHg. A CT scan with contrast showed a Stanford type-A
159 dissection with an intimal flap extending the full length of the aorta from the aortic
160 valve into both iliac arteries (Figure 1B). He underwent open aortic repair and a
161 surgical specimen was recovered for further examination. Histologic examination
162 showed fragmentation and disruption of the aortic elastic fibers and cystic medial
163 necrosis (Figure 1C).

164

165 **Sequencing and variant identification**

166 DNA sequencing from the peripheral blood of the index case identified a missense
167 variant (c.958C>T) (NM_003238.3) in exon 6 of the TGFB2 gene (NG_027721.1).
168 This variant causes a p.(Arg320Cys) substitution in a highly conserved region of

169 TGFB2 (Figure 1D). The variant was also detected in the uncle (III:1) and two
170 currently asymptomatic teenage family members (IV:3) and (IV:5).

171

172 **TGFB1 and TGFB2 expression in the aorta**

173 Immunofluorescent imaging showed markedly enhanced TGFB1 and TGFB2
174 expression in the aorta of the index case compared to age and gender-matched
175 controls (Figure 2 and 3). This was confirmed by immunoblotting for both proteins in
176 the aorta of IV:10 versus controls where the upregulation of TGFB1 was particularly
177 striking (Figure 2 and 3).

178

179 **Discussion**

180

181 The p.(Arg320Cys) substitution is in a highly evolutionarily conserved region of
182 TGFB2 and has a strong *in silico* prediction for pathogenicity [11]. However, there
183 has been no evidence to confirm its functional effects [11]. We show for the first time
184 that this variant does induce striking up-regulation of both TGFB1 and TGFB2 in the
185 vessel wall of a subject with the variant. While this is unexplained by a loss-of-
186 function variant in TGFB2, this signature of enhanced TGF β signaling is believed to
187 play a central role in the aortic dilatation and aneurysms seen in LDS, Marfan
188 syndrome and other inherited aortopathies[15].

189 Of note, haploinsufficient TGFB2^{+/-} mice develop aortic root dilatation and
190 aneurysm and have a higher expression of phosphorylated SMAD2/3 and
191 extracellular signal-regulated kinases (ERK1/2), indicating up-regulation of the TGF β
192 canonical (SMAD dependent) and non-canonical (SMAD independent) pathways [6].
193 The canonical pathway is involved in stimulating elastin and collagen while

194 repressing ECM degradation by inducing endogenous tissue inhibitor of
195 metalloproteinases 1 and 3. These changes disrupt the normal architecture of the
196 vessel wall [2]. Less is known about the role of the non-canonical pathway, however
197 enhanced ERK activity appears to stimulate the expression of matrix
198 metalloproteinases 2 and 9 to stimulate matrix degradation [2, 15].

199 Another suggestion to resolve the TGF β vascular paradox, posits that other
200 TGFB ligands are overexpressed to compensate for haploinsufficiency of a given
201 TGFB ligand. This shift in ligand usage is seen with higher TGFB1 expression in
202 TGFB2^{+/-} mice [6] and in our index case. The high TGFB1/2 expression may even be
203 a “repair process” by mesenchymal cells following damage to ECM [3].

204 As aortic aneurysm and dissection may be the only manifestation of LDS4,
205 identifying family members with the variant is crucial for surveillance to improve
206 clinical outcome. The striking activation of TGF β signaling in these patients also
207 suggests this may be a future therapeutic target for LDS.

208

209 **Acknowledgements**

210 Raya Al Maskari has a PhD studentship funded by the Omani government.

211

212 **Conflict of interest:** The authors declare no conflict of interest.

213

214 **Author contributions**

215 RAM, Y, SC and NF did the bench work; RAM did all the confocal imaging and
216 blotting; SM provided medical genetics diagnostics and advice; DZ provided
217 pathology services and advice; IB identified the pedigree and gave clinical advice;
218 KMO conceived and ran the project and wrote the manuscript with RAM.

220 **References**

- 221 1. Loeys BL, Dietz HC. Loeys-Dietz Syndrome. In: Pagon RA AM, Ardinger HH,
222 et al, editors., ed. *GeneReviews® [Internet]*. University of Washington,
223 Seattle: Seattle (WA) 2013.
- 224 2. Jones JA, Spinale FG, Ikonomidis JS. Transforming growth factor-beta
225 signaling in thoracic aortic aneurysm development: a paradox in
226 pathogenesis. *J Vasc Res* 2009; **46**:119-137.
- 227 3. Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-
228 beta function. *J Biochem* 2012; **152**: 321-329.
- 229 4. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular,
230 craniofacial, neurocognitive and skeletal development caused by mutations in
231 TGFB1 or TGFB2. *Nat Genet* 2005; **37**: 275-281.
- 232 5. van de Laar IM, Oldenburg RA, Pals G, et al. Mutations in SMAD3 cause a
233 syndromic form of aortic aneurysms and dissections with early-onset
234 osteoarthritis. *Nat Genet* 2011; **43**: 121-126.
- 235 6. Lindsay ME, Schepers D, Bolar NA, et al. Loss-of-function mutations in
236 TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. *Nat*
237 *Genet* 2012; **44**: 922-927.
- 238 7. Bertoli-Avella AM, Gillis E, Morisaki H, et al. Mutations in a TGF-beta ligand,
239 TGFB3, cause syndromic aortic aneurysms and dissections. *J Am Coll*
240 *Cardiol* 2015; **65**: 1324-1336.
- 241 8. MacCarrick G, Black JH, 3rd, Bowdin S, et al. Loeys-Dietz syndrome: a primer
242 for diagnosis and management. *Genet Med* 2014; **16**: 576-587.
- 243 9. Boileau C, Guo DC, Hanna N, et al. TGFB2 mutations cause familial thoracic
244 aortic aneurysms and dissections associated with mild systemic features of
245 Marfan syndrome. *Nat Genet* 2012; **44**: 916-921.
- 246 10. Ritelli M, Chiarelli N, Dordoni C, et al. Further delineation of Loeys-Dietz
247 syndrome type 4 in a family with mild vascular involvement and a TGFB2
248 splicing mutation. *BMC Med Genet* 2014; **15**: 91.
- 249 11. Gago-Diaz M, Blanco-Verea A, Teixido-Tura G, et al. Whole exome
250 sequencing for the identification of a new mutation in TGFB2 involved in a
251 familial case of non-syndromic aortic disease. *Clin Chim Acta* 2014; **437**: 88-
252 92.
- 253 12. Leutermann R, Sheikhzadeh S, Brockstadt L, et al. A 1-bp duplication in
254 TGFB2 in three family members with a syndromic form of thoracic aortic
255 aneurysm. *Eur J Hum Genet* 2014; **22**: 944-948.
- 256 13. Renard M, Callewaert B, Malfait F et al. Thoracic aortic-aneurysm and
257 dissection in association with significant mitral valve disease caused by
258 mutations in TGFB2. *Intern J Cardiol* 2013; **165**: 584-587.
- 259 14. Akhurst RJ. The paradoxical TGF-beta vasculopathies. *Nat Genet*. 2012; **44**:
260 838-839.
- 261 15. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from
262 heritable conditions. *Nature* 2011; **473**: 308-316.
- 263

265 **Titles and legends to figures**

266 **Figure 1 Clinical and Molecular Findings A.** Family pedigree with multiple cases
267 of aneurysms and dissections suggesting autosomal dominant inheritance. The
268 variant was detected in the index case (IV:10) and III:1, IV:3 and IV:5. **B.** CT images
269 showing an intimal flap (red arrows) extending from the aortic valve into the thoracic
270 aorta. **C.** Elastin staining of IV:10 aorta showing extensive elastic fibre fragmentation
271 at the site of dissection (scale bar=6mm). **D.** Sequencing chromatogram showing a
272 missense mutation (c.958C>T) in exon 6 of TGFB2. The mutation is in a region of
273 TGFB2 that is highly conserved across species. SP; signal peptide, LAP; latency-
274 associated-peptide.

275
276 **Figure 2 Aortic Expression of TGFB2 A.** Western blots of aortic TGFB2
277 expression in IV:10 compared to two age-matched controls, TS218 and TS199.
278 Signal intensities of TGFB2 normalized against β Actin indicate a twofold higher
279 expression of TGFB2 in the mutant sample. **B.** Immunofluorescent staining of
280 TGFB2 (green) shows increased expression in the aortic wall of IV:10 compared to
281 TS218 and TS199. Elastic fibres appear as blue (autofluorescence) and nuclei are
282 counterstained red (scale bar=50uM and the right-hand images are zoomed).

283
284 **Figure 3 Aortic Expression of TGFB1 A.** Western blots of aortic TGFB1
285 expression in IV:10 compared to two age-matched controls, TS218 and TS199.
286 Signal intensities of TGFB1 normalized against β Actin indicate a 15-fold higher
287 expression of TGFB1 in the mutant sample. **B.** Immunofluorescent staining of
288 TGFB1 (green) shows increased expression in the aortic wall of IV:10 compared to
289 TS218 and TS199. Elastic fibres appear as blue (autofluorescence) and nuclei are
290 counterstained red (scale bar=50uM and the right-hand images are zoomed).

291

Figure 1







Figure 2





Figure 3

